Orthocell Expands into Thai Market with Remplir™ Approval

Orthocell Ltd ( (AU:OCC) ) has provided an update.

Orthocell Ltd has received regulatory approval from the Thai FDA to commence sales of its nerve repair product Remplir™ in Thailand, a market valued at US$84 million. This approval, achieved through an expedited registration pathway, significantly enhances Orthocell’s presence in the Asia Pacific region and is expected to drive revenue growth. The company plans to partner with a local distributor and anticipates first sales in the second half of 2025. With a strong cash reserve and no debt, Orthocell is well-positioned to expand its global footprint and capitalize on the growing demand for nerve repair solutions.

More about Orthocell Ltd

Orthocell Ltd is a regenerative medicine company based in Perth, Australia. The company specializes in developing and commercializing products for the repair and regeneration of damaged nerves, with its flagship product being Remplir™, a collagen wrap used in nerve repair surgery. Orthocell operates in a global market with approvals in the US, Australia, New Zealand, Singapore, and now Thailand, targeting a large addressable nerve repair market.

YTD Price Performance: -4.80%

Average Trading Volume: 1,556,206

Technical Sentiment Signal: Sell

Current Market Cap: A$312.1M

Learn more about OCC stock on TipRanks’ Stock Analysis page.